Cheolwon Suh

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson et al. · Journal of Clinical Oncology · 2019 · 616 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study

Jeeyun Lee, Cheolwon Suh, Young Hyeh Ko et al. · Journal of Clinical Oncology · 2005 · 614 citations · Full text

Medicine, Oncology, Cancer Immunology +12

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology · 2011 · 602 citations

Pharmacy, Oncology, Pharmacotherapy +13

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

Seok Jin Kim, Dok Hyun Yoon, Arnaud Jaccard et al. · The Lancet Oncology · 2016 · 386 citations · Full text

Medicine, Clinical Sciences, Oncology +15